FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology, microbiology and medicine. A combination contains a first ingredient and a second ingredient. The first ingredient represents a bacterial cell which contains at least one recombinant nucleic acid molecule, a coding peptide and a polypeptide of phagolysosome fusion. The second ingredient represents a biologically active agent inducing an immune response to cancer or an infectious disease. There are also described pharmaceutical compositions and methods of treating using the above compound.
EFFECT: what is presented is a combination inducing the immune response to cancer or the infectious disease.
69 cl, 9 dwg, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS FOR WT1-SPECIFIC IMMUNOTHERAPY | 1999 |
|
RU2237674C2 |
| TUBERCULOSIS VACCINE WITH IMPROVED STRENGTH | 2004 |
|
RU2342400C2 |
| USE OF MONOMYCOLYL GLYCEROL (MMG) AS ADJUVANT | 2008 |
|
RU2479317C2 |
| PROSTATE-ASSOCIATED ANTIGENS AND IMMUNOTHERAPY SCHEMES BASED ON VACCINES | 2013 |
|
RU2609651C2 |
| PROSTATE-ASSOCIATED ANTIGENS AND IMMUNOTHERAPEUTIC REGIMENS BASED ON VACCINES | 2013 |
|
RU2737765C2 |
| CONDITIONALLY REPLICATING CYTOMEGALOVIRUS AS VACCINE AGAINST CMV | 2012 |
|
RU2670012C1 |
| CONDITIONALLY REPLICATING CYTOMEGALOVIRUS AS VACCINE AGAINST CMV | 2012 |
|
RU2611198C2 |
| INTRACELLULAR DELIVERY OF BIOMOLECULES FOR IMMUNE RESPONSE MODULATION | 2019 |
|
RU2819143C2 |
| MULTIVALENT VACCINE AGAINST BREAST CANCER | 2013 |
|
RU2645085C2 |
| VIRAL PARTICLE RELEASED AFTER INFECTION OF HUMAN CYTOMEGALOVIR (HCMV) OF MAMMALS CELLS, CONTAINING FUSION PROTEIN, AND ITS APPLICATION | 2011 |
|
RU2623172C2 |
